Segal Trials

Posts about:

Psychedelics Research

Understanding Anxiety Better: Continuing the Conversation from Last Year's Discussion

Welcome to Part 2 of our exploration into anxiety. Last year, we discussed common behaviors and symptoms associated with Social Anxiety Disorder in our blog: If you can relate, you may have social anxiety disorder. Today, we delve deeper, offering new insights and the latest information to help you understand this pervasive condition. If you find yourself relating to these experiences, it may be time to consider professional avenues, including potential participation in a clinical trial for anxiety.

Read More

The FDA Panel’s Rejection of MDMA: Not a Stop Sign for the Psychedelic Industry

The team at Segal Trials’ Center for Psychedelic Research closely followed the recent session of the FDA’s Psychopharmacologic Drugs Advisory Committee. This pivotal meeting focused on the New Drug Application (NDA) submitted by Lykos Therapeutics for MDMA-assisted therapy for Post-Traumatic Stress Disorder (PTSD). Despite compelling presentations and data showing significant efficacy and a low incidence of serious adverse events, the committee voted against FDA approval. This vote, however, is non-binding, and the FDA’s final decision is expected by August 11, 2024.

Read More

Workplace Strategies to Handle Toxicity & Promote Mental Health

Welcome to the brighter side of corporate culture, where we not only navigate the choppy waters of workplace dynamics but also offer a lifeline to those struggling with mental health issues like generalized anxiety disorder, social anxiety disorder, and depression. Today, we'll delve into managing challenging personalities at work and how Segal Trials, a clinical trials company, provides alternative care options to help you thrive both professionally and personally.

Read More